Across TCGA pan-cancer cohorts, PMS2CL RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated PMS2CL data layer compared with 3 for mutation status.
The strongest signal is observed in kidney chromophobe (KICH), where higher PMS2CL RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PMS2CL expression acts as an unfavorable survival marker, although some lineages such as PAAD and LAML show a favorable association.
KICH, CESC, and COAD are the cancer types where PMS2CL RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.